Navigation Links
Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
Date:12/8/2008

. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic product, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. Halozyme also has a number of different enzymes in its portfolio that target significant areas of unmet medical need. For more information visit http://www.halozyme.com.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning Roche's progress under the collaboration) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

     Halozyme Contact                        Media Contacts
     Robert H. Uhl                           Karen Sparks / Joleen Schultz
     Senior Director, I
'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
2. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
3. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
6. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
7. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
8. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
9. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
10. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
11. Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 2015 Physician E-sampling is becoming well established ... a key marketing sales tactic in recent years. However, ... as a supplement to traditional sampling. ... physician E-sampling has been seeded across multiple therapeutic areas- ... E-sampling has been in place for five or more ...
(Date:9/4/2015)... RARITAN, N.J. , Sept. 4, 2015  Janssen ... U.S. Food and Drug Administration (FDA) has accepted ... for daratumumab as a treatment for patients with ... proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), ... lines of therapy, including a PI and an ...
(Date:9/4/2015)... -- Fair Rate Funding, a lawsuit funding firm located in ... increase in lawsuit filings in connection with the blood thinning ... Philadelphia Court of Common Pleas has ... Louisiana multi---district litigation (MDL), located in ... Louisiana , the filings are also on the ...
Breaking Medicine Technology:Current and Future Trends in Physician E-Sampling Programs for the Pharmaceutical Industry 2U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 2U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 3U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 4U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 5U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 6U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 7Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 2Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 3
... -- MAP Pharmaceuticals, Inc. (Nasdaq: ... the Phase 3 FREEDOM-301 study of  LEVADEX™ orally inhaled ... titled MAP0004, Orally Inhaled DHE: A Randomized, Controlled Study ... online and will appear in the April edition, Volume ...
... 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... of medical devices worldwide, announced today that it will ... in Shenzhen, China from April 16 to April 19, ... devices from its three core product segments: patient monitoring ...
Cached Medicine Technology:Data from FREEDOM-301 Study for LEVADEX™ Orally Inhaled Migraine Drug Published in 'Headache' 2Data from FREEDOM-301 Study for LEVADEX™ Orally Inhaled Migraine Drug Published in 'Headache' 3Data from FREEDOM-301 Study for LEVADEX™ Orally Inhaled Migraine Drug Published in 'Headache' 4Mindray Medical to Exhibit New Products at 65th China International Medical Equipment Fair 2
(Date:9/4/2015)... , ... September 04, 2015 , ... ... the surrounding communities, is launching a charity effort to provide for the family ... to as an enlarged heart, restrictive cardiomyopathy often leads to diastolic dysfunction – ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Keeping mold top ... around the home is quite common. Mold can grow anywhere - on carpet, clothing, ... pipes. Checking for excessive moisture and water in the home is key to preventing ...
(Date:9/4/2015)... , ... September 04, 2015 , ... ... line of personal humidifying medical devices, announced its only mission and research focus: ... Aqua® Research Founder Sharon Kleyne, body water evaporation is becoming dangerously accelerated. As ...
(Date:9/4/2015)... ... September 04, 2015 , ... Lalonde Gordon ran a 44.64 ... up with victory in the men’s 400 meters final, with an impressive 44.89 seconds ... Championships in San Jose, Costa Rica in August 2015. The 44.64 time is a ...
(Date:9/4/2015)... ... September 04, 2015 , ... EMED Jamaica ... announced that it has entered into a multi-year agreement with Health City Cayman ... bridge the link between American healthcare, Jamaican healthcare and Health City Cayman Islands ...
Breaking Medicine News(10 mins):Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 3Health News:September is Mold Awareness Month 2Health News:September is Mold Awareness Month 3Health News:September is Mold Awareness Month 4Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 3Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 4Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 5Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 6
... ... Awareness Month this August , ... CA (Vocus) August 11, 2009 -- Did you know that cataracts are the leading ... people over age 65 have some degree of cataract development. , , , , ,Moreover, ...
... ... to provide a new and advanced platform to migrate, manage and streamline message exchange ... solution. , ... Monica, Calif. (PRWEB) August 11, 2009 -- Asante Health System , based in ...
... A ... surgical procedure in the United States is breast augmentation, with more than 355,000 of them ... says not all women end up being happy with their results, and breast revision surgery ... ...
... ... U.S.-based ZyDoc Medical Transcription, a technology leader in ... it has completed acquisition of Pennsylvania-based Administrative Advantage, a full-service ... extends a prior strategic business alliance and strengthens market share ...
... Take Medications, Yet Just Over 1 in 4 are Aware of Potential ... According to a new study released today by the AAA ... have had one or more medical condition and 78 percent use one ... potential impact on driving performance associated with those medications. , , ...
... , , DETROIT, Aug. 10 Every ... but given the abuse potential many wind up getting hooked on these drugs ... topic of an interview that aired today on the Rick Sanchez show on ... was the title of the interview and it featured Narconon Graduate, Dominick Assante, ...
Cached Medicine News:Health News:EyeCare America Works to Prevent Blindness Caused by Cataracts 2Health News:EyeCare America Works to Prevent Blindness Caused by Cataracts 3Health News:Community Hospital System Integrates Patient Data with Orion Health 2Health News:Community Hospital System Integrates Patient Data with Orion Health 3Health News:Re-Envision Your Look: Dr. David Whiteman Suggests Breast Revision Surgery as Solution for Women Dissatisfied with Prior Procedures 2Health News:Re-Envision Your Look: Dr. David Whiteman Suggests Breast Revision Surgery as Solution for Women Dissatisfied with Prior Procedures 3Health News:ZyDoc Medical Transcription Completes Acquisition of Administrative Advantage 2Health News:ZyDoc Medical Transcription Completes Acquisition of Administrative Advantage 3Health News:ZyDoc Medical Transcription Completes Acquisition of Administrative Advantage 4Health News:ZyDoc Medical Transcription Completes Acquisition of Administrative Advantage 5Health News:Large Majority of Drivers 55 and Older Unaware of Potentially Dangerous Combination of Medications and Driving, Says New AAA Foundation Study 2Health News:Large Majority of Drivers 55 and Older Unaware of Potentially Dangerous Combination of Medications and Driving, Says New AAA Foundation Study 3Health News:Narconon Graduate Lives to Tell Story of Addiction 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: